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Introduction
THYROID NODULES are a common clinical problem. Epi-demiologic studies have shown the prevalence of palpa-
ble thyroid nodules to be approximately 5% in women and
1% in men living in iodine-sufficient parts of the world (1,2).
In contrast, high-resolution ultrasound can detect thyroid
nodules in 19%–67% of randomly selected individuals with
higher frequencies in women and the elderly (3). The clinical
importance of thyroid nodules rests with the need to exclude
thyroid cancer that occurs in 5%–10% depending on age, gen-
der, radiation exposure history, family history, and other fac-
tors (4, 5). Differentiated thyroid cancer, which includes pap-
illary and follicular cancer, comprises the vast majority (90%)
of all thyroid cancers (6). In the United States, approximately
23,500 cases of differentiated thyroid cancer are diagnosed
each year (7), and the yearly incidence may be increasing (8).
In 1996, the American Thyroid Association (ATA) pub-
lished treatment guidelines for patients with thyroid nod-
ules and thyroid cancer (9). Over the last decade, there have
been many advances in the diagnosis and therapy of both
thyroid nodules and differentiated thyroid cancer. Contro-
versy exists in many areas, including the most cost-effective
approach in the diagnostic evaluation of a thyroid nodule,
the extent of surgery for small thyroid cancers, the use of ra-
dioactive iodine to ablate remnant tissue after thyroidec-
tomy, the appropriate use of thyroxine suppression therapy,
and the role of human recombinant thyrotropin. In recogni-
tion of the changes that have taken place in the overall man-
agement of these clinically important problems, the ATA ap-
pointed a task force to reexamine the current strategies that
are used to diagnose and treat thyroid nodules and differ-
entiated thyroid cancer, and to develop clinical guidelines
using principles of evidence-based medicine. Members of the
taskforce included experts in thyroid nodule and thyroid
cancer management with representation by endocrinology,
surgery, and nuclear medicine. Other groups have previ-
ously developed guidelines, including the American Asso-
ciation of Clinical Endocrinologists and the American Asso-
ciation of Endocrine Surgeons (10), the British Thyroid
Association and The Royal College of Physicians (11), and
the National Comprehensive Cancer Network (12), which
have provided somewhat conflicting recommendations be-
cause of the lack of high-quality evidence from randomized
controlled trials.
Materials and Methods
The ATA guidelines taskforce used a strategy similar to
that used by the National Institutes of Health for its Con-
sensus Development Conferences (www.consensus.nih.
gov/about/process.htm), and developed a series of clini-
cally relevant questions pertaining to thyroid nodule and
thyroid cancer diagnosis and treatment. These questions
were as follows:
Thyroid Nodules
• What is the appropriate evaluation of clinically or inci-
dentally discovered thyroid nodule(s)?
 What laboratory tests and imaging modalities are indi-
cated?
 What is the role of fine needle aspiration (FNA)?
• What is the best method of long-term follow-up of patients
with thyroid nodules?
• What is the role of medical therapy of patients with be-
nign thyroid nodules?
• How should thyroid nodules in children and pregnant
women be managed?
Differentiated Thyroid Cancer: Initial Management
• What is the role of preoperative staging with diagnostic
imaging and laboratory tests?
• What is the appropriate operation for differentiated thy-
roid cancer?
• What is the role of postoperative staging systems and
which should be used?
• What is the role of postoperative radioiodine remnant ab-
lation?
• What is the role of thyrotropin suppression therapy?
• Is there a role for adjunctive external beam irradiation or
chemotherapy?
Differentiated Thyroid Cancer: Long-Term
Management
• What are the appropriate features of long-term manage-
ment?
• What is the role of serum thyroglobulin assays?
• What is the role of ultrasound and other imaging tech-
niques during follow-up?
• What is the role of thyrotropin suppression in long-term
follow-up?
• What is the most appropriate management of patients
with metastatic disease?
• How should thyroglobulin positive, scan negative patients
be managed?
• What is the role of external radiation therapy
• What is the role of chemotherapy?
• What are directions for future research?
A 2-day meeting of the taskforce was held on January
21–23, 2005. Prior to the meeting, the taskforce members un-
dertook a complete literature review. Relevant articles were
identified by searching MEDLINE using the following search
terms: {THRYOID NODULE/diagnosis, drug therapy, sur-
gery, therapy, ultrasonography} or {CANCER} or {CARCI-
NOMA} and {THYROID} and {FOLLICULAR CARCI-
NOMA} or {PAPILLARY CACINOMA} and {FOLLOW-UP}
and {TREATMENT} and {RECURRENCE}. All English-
language papers published between 1995 and December
2004 were reviewed and categorized in tabular form by date,
author, subject, and whether it represented a randomized
controlled trial, meta-analysis, or clinical case series. Rele-
vant review articles, book chapters, and pre-1995 articles
were also supplied by taskforce members. The taskforce cat-
egorized the published data using modified criteria adopted
from the U.S. Preventive Services Task Force (USPSTF) (13).
The taskforce then made specific recommendations, rated the
strength of the recommendation using the schema proposed
by the USPSTF (Table 1). Given the paucity of randomized
controlled trials in the treatment of thyroid cancer, the panel
relied on all the available published evidence. When evi-
dence was judged to be insufficient, the taskforce members
also relied on their experience and judgment to answer the
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questions that had been posed. The taskforce met again in
April 2005 and in June 2005 to refine the document and in-
clude new references. Supplementing these meetings were
multiple teleconferences and detailed e-mail communica-
tions that continued through July 2005.
Results
Thyroid nodules
A thyroid nodule is a discrete lesion within the thyroid
gland that is palpably and/or ultrasonographically distinct
from the surrounding thyroid parenchyma. However, some
palpable lesions may not correspond to distinct radiologic
abnormalities (14). Such abnormalities do not meet the strict
definition for thyroid nodules. Other nonpalpable nodules
are easily seen on ultrasound or other anatomic imaging
studies, and are termed incidentally discovered nodules or
“incidentalomas.” Nonpalpable nodules have the same risk
of malignancy as palpable nodules with the same size (15).
Generally, only nodules larger than 1 cm should be evalu-
ated, because they have the potential to be clinically signif-
icant cancers. Occasionally, there may be nodules smaller
than 1 cm that require evaluation, because of suspicious ul-
trasound findings, a history of head and neck irradiation, or
a positive family history of thyroid cancer.
What is the appropriate evaluation of clinically or
incidentally discovered thyroid nodule(s)?
With the discovery of a thyroid nodule, a complete his-
tory and physical examination focusing on the thyroid gland
and adjacent cervical lymph nodes should be performed (Fig.
1). Pertinent historical factors predicting malignancy include
a history of head and neck irradiation, total body irradiation
for bone marrow transplantation (16), family history of thy-
roid carcinoma in a first-degree relative, exposure to fallout
from Chernobyl under the age of 14 years (17), and rapid
growth and hoarseness. Pertinent physical findings sug-
gesting possible malignancy include vocal cord paralysis, ip-
silateral cervical lymphadenopathy and fixation of the nod-
ule to surrounding tissues.
What laboratory tests and imaging modalities 
are indicated?
Serum thyrotropin and imaging studies. With the discov-
ery of a thyroid nodule larger than 1–1.5 cm in any diame-
ter, a serum thyrotropin (TSH) level should be obtained. If
the serum TSH is subnormal, a radionuclide thyroid scan
should be obtained to document whether the nodule is func-
tioning (i.e., has tracer uptake greater than the surrounding
normal thyroid), isofunctioning or “warm” (i.e., has tracer
uptake equal to the surrounding thyroid), or nonfunctioning
(i.e., has uptake less than the surrounding thyroid tissue). Be-
cause functioning nodules rarely harbor malignancy, if one
is found that corresponds to the clinical nodule, no additional
cytologic evaluation is necessary. If overt or subclinical hy-
perthyroidism is present, additional evaluation is required.
R1. Measure serum TSH in the initial evaluation of a patient
with a thyroid nodule—Recommendation C
Diagnostic thyroid ultrasound should be performed un-
less the serum TSH is suppressed. Thyroid ultrasound can
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TABLE 1. STRENGTH OF PANELISTS’ RECOMMENDATIONS BASED ON AVAILABLE EVIDENCE
Rating Definition
Strongly recommends. The recommendation is based on good evidence that the service or
intervention can improve important health outcomes. Evidence includes consistent results from
well-designed, well-conducted studies in representative populations that directly assess effects
on health outcomes.
Recommends. The recommendation is based on fair evidence that the service or intervention can
improve important health outcomes. The evidence is sufficient to determine effects on health
outcomes, but the strength of the evidence is limited by the number, quality, or consistency of
the individual studies; generalizability to routine practice; or indirect nature of the evidence on
health outcomes.
C Recommends. The recommendation is based on expert opinion.
D Recommends against. The recommendation is based on expert opinion.
Recommends against. The recommendation is based on fair evidence that the service or
intervention does not improve important health outcomes or that harms outweigh benefits.
Strongly recommends against. The recommendation is based on good evidence that the service or
intervention does not improve important health outcomes or that harms outweigh benefits.
Recommends neither for nor against. The panel concludes that the evidence is insufficient to
recommend for or against providing the service or intervention because evidence is lacking that
the service or intervention improves important health outcomes, the evidence is of poor quality,
or the evidence is conflicting. As a result, the balance of benefits and harms cannot be
determined.






answer the following questions: Is there truly a nodule that
corresponds to the palpable abnormality? Is the nodule
greater than 50% cystic? Is the nodule located posteriorly in
the thyroid gland? These last two features might decrease
the accuracy of fine needle aspiration biopsy performed with
palpation (18,19). Also, there may be other thyroid nodules
present that require biopsy based on their size and appear-
ance (14,20,21). Even if the TSH is elevated, FNA is recom-
mended because the rate of malignancy in nodules is simi-
lar in thyroid glands involved with Hashimoto’s thyroiditis
as in normal thyroid glands (22).
R2. Thyroid sonography should be performed in all patients
with one or more suspected thyroid nodules—Recommen-
dation B
Other laboratory testing:
Serum thyroglobulin measurement. Serum thyroglobulin
levels can be elevated in most thyroid diseases and is an in-
sensitive and nonspecific test for thyroid cancer (23).
R3. Routine measurement of serum thyroglobulin for initial
evaluation of thyroid nodules is not recommended—Rec-
ommendation F
Serum calcitonin measurement. The utility of serum cal-
citonin has been evaluated in a series of prospective, non-
randomized studies (24–26). The data suggest that the use of
routine serum calcitonin for screening may detect C-cell hy-
perplasia and medullary thyroid cancer at an earlier stage
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FIG. 1. Algorithm for the evaluation of patients with one or more thyroid nodules. aIf the scan does not show uniform
distribution of tracer activity, ultrasound may be considered to assess for the presence of a cystic component
and overall survival may be improved. However, there re-
main unresolved issues of sensitivity, specificity, assay per-
formance, and cost effectiveness. Furthermore, most studies
rely on pentagastrin stimulation testing to increase speci-
ficity and this drug is no longer available in the United States.
However, if the unstimulated serum calcitonin determina-
tion has been obtained and the level is greater than 100
pg/mL, medullary cancer is likely present (27).
R4. The panel cannot recommend either for or against the rou-
tine measurement of serum calcitonin—Recommendation I
What is the role of FNA biopsy?
FNA is the most accurate and cost effective method for
evaluating thyroid nodules. Traditionally FNA biopsy re-
sults are divided into four categories: nondiagnostic, malig-
nant, indeterminate or suspicious for neoplasm, and benign.
Nondiagnostic biopsies are those that fail to meet specified
criteria for adequacy that have been previously established
(5). Such biopsies need to be repeated using ultrasound guid-
ance (28). Some nodules, particularly those that are cystic,
continue to yield nondiagnostic cytology results despite re-
peated biopsies, and may be malignant at the time of sur-
gery (29,30).
R5. FNA is the procedure of choice in the evaluation of thy-
roid nodules—Recommendation A
Nondiagnostic aspirates
R6. Cystic nodules that repeatedly yield nondiagnostic aspi-
rates need close observation or surgical excision. Surgery
should be more strongly considered if the cytologically non-
diagnostic nodule is solid—Recommendation A
Aspirates suggesting malignancy
R7. If a cytology result is diagnostic of malignancy, surgery
is recommended (31)—Recommendation A
Indeterminate cytology
Indeterminate cytology, often reported as “suspicious,”
“follicular lesion,” or “follicular neoplasm,” can often be
found in 15%–30% of FNA specimens. While certain clinical
features such as gender and nodule size (32) or cytologic fea-
tures such as presence of atypia (33) can improve the diag-
nostic accuracy in patients with indeterminate cytology,
overall predictive values are still low. Many molecular mark-
ers have been evaluated to improve diagnostic accuracy for
indeterminate nodules (34,35) but none can be recommended
because of insufficient data.
R8. At the present time, the use of specific molecular mark-
ers to improve the diagnostic accuracy of indeterminate nod-
ules is not recommended—Recommendation I
R9. If the cytology reading is indeterminate (often termed
“suspicious,” “follicular lesion,” or “follicular neoplasm”), a
radioiodine thyroid scan should be considered, if not already
done. If a concordant autonomously functioning nodule is
not seen, lobectomy or total thyroidectomy should be con-
sidered—Recommendation B
R10. If the reading is “suspicious for papillary carcinoma or
Hürthle cell neoplasm,” a radionuclide scan is not needed,
and either lobectomy or total thyroidectomy is recom-
mended—Recommendation A (36)
Benign cytology
R11. If the nodule is benign on cytology, further immediate
diagnostic studies or treatment are not routinely required—
Recommendation A
Multinodular goiters
Patients with multiple thyroid nodules have the same risk
of malignancy as those with solitary nodules (14,37). A di-
agnostic ultrasound should be performed to delineate the
nodules, but if only the “dominant” or largest nodule is as-
pirated, the thyroid cancer may be missed (14). Sonographic
characteristics are superior to nodule size for identifying
nodules that are more likely to be malignant (37,38) and in-
clude the presence of microcalcifications, hypoechogenicity
(darker than the surrounding thyroid parenchyma) of a solid
nodule, and intranodular hypervascularity (37,38). The de-
tection of microcalcifications and nodular vascularity has
good interobserver reliability (39).
R12a. In the presence of two or more thyroid nodules larger
than 1–1.5 cm, those with a suspicious sonographic appear-
ance should be aspirated preferentially—Recommendation B
R12b. If none of the nodules has a suspicious sonographic
appearance and multiple sonographically similar coalescent
nodules are present, the likelihood of malignancy is low and
it is reasonable to aspirate the largest nodules only—Rec-
ommendation C
R13. A low or low-normal serum TSH concentration may
suggest the presence of autonomous nodule(s). A radioio-
dine scan should be performed and directly compared to the
ultrasound images to determine functionality of each nod-
ule larger than 1–1.5 cm. FNA should then be considered
only for those isofunctioning or nonfunctioning nodules,
among which those with suspicious sonographic features
should be aspirated preferentially—Recommendation B
What is the best method of long-term follow-up of patients
with thyroid nodules?
Thyroid nodules diagnosed as benign require follow-up
because of a low, but not negligible, false-negative rate of up
to 5% with FNA (40,41). While benign nodules may decrease
in size, they often increase in size, albeit slowly (42). Nod-
ule growth is not in and of itself an indication of malignancy,
but growth is an indication for repeat biopsy. For nodules
with benign cytologic results, recent series report a higher
false negative rate with palpation FNA (1%–3%) (43–45) than
with ultrasound FNA (0.6%) (44). In one study investigating
the value of routine reaspirations of benign nodules, the nod-
ule grew in the three patients who were subsequently found
to have thyroid cancer (37). Because the accuracy of physi-
cal examination for nodule size is likely inferior to that of ul-
trasound (21), it is recommended that serial ultrasound be
used in follow-up of thyroid nodules to detect clinically sig-
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nificant changes in size. There is no consensus on the defi-
nition of nodule growth, however, or the threshold that
would require rebiopsy. Some groups suggest a 15% increase
in nodule volume, while others recommend measuring a
change in the mean nodule diameter (42,46). One reasonable
definition of growth is a 20% increase in nodule diameter
with a minimum increase in two or more dimensions of at
least 2 mm. The false-negative rate for benign thyroid nod-
ules on repeat FNA is low (47).
R14. Easily palpable benign nodules do not require sono-
graphic monitoring, but patients should be followed clinically
at 6–18 month intervals. It is recommended that all other be-
nign thyroid nodules be followed with serial ultrasound ex-
aminations 6–18 months after initial FNA. If nodule size is
stable, the interval before the next follow-up clinical exami-
nation or ultrasound may be longer—Recommendation B
R15. If there is evidence for nodule growth either by palpa-
tion or sonographically, repeat FNA, preferably with ultra-
sound guidance—Recommendation B
What is the role of medical therapy for benign 
thyroid nodules?
Evidence from multiple randomized control trials and
three metaanalyses suggest that thyroid hormone in doses
that suppress the serum TSH to subnormal levels may result
in a decrease in nodule size in regions of the world with bor-
derline low iodine intake. Data in iodine sufficient popula-
tions are less compelling (48–50).
R16. The panel does not recommend routine suppression
therapy of benign thyroid nodules—Recommendation F
R17. Patients with growing nodules that are benign after re-
peat biopsy should be considered for continued monitoring
or intervention with surgery based on symptoms and clini-
cal concern—Recommendation C. There are no data on the
use of levothyroxine in this subpopulation of patients—Rec-
ommendation I
How should thyroid nodules in children and pregnant
women be managed?
Thyroid nodules in children. Thyroid nodules occur less
frequently in children than in adults. In one study in which
approximately 5000 children aged 11 to 18 were assessed an-
nually in the southwestern United States, palpable thyroid
nodules occurred in approximately 20 per 1000 children,
with an annual incidence of 7 new cases per 1000 children
(51). Some studies have shown the frequency of malignancy
to be higher in children than adults, in the 15%–20% range
(52–54), whereas other data have suggested that the fre-
quency of thyroid cancer in childhood thyroid nodules is
similar to that of adults (55,56). FNA biopsy is sensitive and
specific in the diagnosis of childhood thyroid nodules
(53–55).
R18. The diagnostic and therapeutic approach to one or more
thyroid nodules in a child should be the same as it would
be in an adult (clinical evaluation, serum TSH, ultrasound,
FNA)—Recommendation A
Thyroid nodules in pregnant women. It is uncertain if thy-
roid nodules discovered in pregnant women are more likely
to be malignant than those found in nonpregnant women
(57), because there are no population-based studies on this
question. The evaluation is the same as for a nonpregnant
patient, with the exception that a radionuclide scan is con-
traindicated.
R19. For euthyroid and hypothyroid pregnant women with
thyroid nodules, FNA should be performed. For women with
suppressed serum TSH levels that persist after the first
trimester, FNA may be deferred until after pregnancy when
a radionuclide scan can be performed to evaluate nodule
function—Recommendation A
If the FNA cytology is consistent with thyroid cancer, sur-
gery is recommended. However, there is no consensus about
whether surgery should be performed during pregnancy or
after delivery. To minimize the risk of miscarriage, surgery
during pregnancy should be done before 24 weeks’ gesta-
tion (58). However, thyroid cancer discovered during preg-
nancy does not behave more aggressively than that diag-
nosed in a similar aged group of nonpregnant women
(59,60). A retrospective study of pregnant women with dif-
ferentiated thyroid cancer found there to be no difference in
either recurrence or survival rates between women operated
on during or after their pregnancy (60). Furthermore, retro-
spective data suggest that treatment delays of less than 1 year
from the time of thyroid cancer discovery do not adversely
effect patient outcome (61).
R20. A nodule with malignant cytology discovered early in
pregnancy should be monitored sonographically and if it
grows substantially (as defined above) by 24 weeks’ gesta-
tion, surgery should be performed at that point. However,
if it remains stable by midgestation or if it is diagnosed in
the second half of pregnancy, surgery may be performed af-
ter delivery—Recommendation C
Differentiated Thyroid Cancer: Initial Management
Goals of initial therapy of differentiated thyroid cancer are:
1. To remove the primary tumor, disease that has extended beyond
the thyroid capsule, and involved cervical lymph nodes. Com-
pleteness of surgical resection is an important determi-
nant of outcome, while residual metastatic lymph nodes
represent the most common site of disease recurrence
(62–64).
2. To minimize treatment- and disease-related morbidity. The ex-
tent of surgery and the experience of the surgeon both
play important roles in determining the risk of surgical
complications (65,66).
3. To permit accurate staging of the disease. Because disease
stage can assist with prognostication, disease manage-
ment and follow-up strategies, accurate postoperative
staging is a crucial element in the management of patients
with differentiated thyroid cancer (67,68).
4. To facilitate postoperative treatment with radioactive iodine,
where appropriate. For patients undergoing radioiodine
remnant ablation, or radioiodine treatment of residual or
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metastatic disease, removal of all normal thyroid tissue is
an important element of initial surgery (69). Near-total or
total thyroidectomy also may reduce the risk for recur-
rence within the contralateral lobe (70).
5. To permit accurate long-term surveillance for disease recur-
rence. Both radioiodine whole-body scanning and mea-
surement of serum thyroglobulin are affected by residual
normal thyroid tissue. Where these approaches are uti-
lized for long-term monitoring, near-total or total thy-
roidectomy is required (71).
6. To minimize the risk of disease recurrence and metastatic
spread. Adequate surgery is the most important treatment
variable influencing prognosis, while radioactive iodine
treatment, thyrotropin suppression and external beam ir-
radiation each play adjunctive roles in at least some pa-
tients (71–74).
What is the role of preoperative staging with diagnostic
imaging and laboratory tests?
Neck imaging. Differentiated thyroid carcinoma (particu-
larly papillary carcinoma) involves cervical lymph nodes in
20%–50% of patients in most series using standard patho-
logic techniques (75–79), and may be present even when the
primary tumor is small and intrathyroidal (37,80). The fre-
quency of micrometastases may approach 90%, depending
on the sensitivity of the detection method (81,82). Preopera-
tive ultrasound identifies suspicious cervical adenopathy in
20%–31% of cases, potentially altering the surgical approach
(83,84), although prospective studies are needed.
Accurate staging is important in determining the progno-
sis and tailoring treatment for patients with differentiated
thyroid cancer. However, unlike many tumor types, the pres-
ence of metastatic disease does not obviate the need for sur-
gical excision of the primary tumor in differentiated thyroid
cancer (85). Because metastatic disease may respond to ra-
dioiodine therapy, removal of the thyroid as well as the pri-
mary tumor and accessible loco-regional disease remains an
important component of initial treatment even in metastatic
disease.
As ultrasound evaluation is uniquely operator dependent,
alternative imaging procedures may be preferable in some
clinical settings, though the sensitivity of computed tomog-
raphy (CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET) scan remain unknown in this
setting. These alternative imaging modalities, as well as
laryngoscopy and endoscopy, may also be useful in the as-
sessment of large, rapidly growing, or invasive tumors, to
assess the involvement of extrathyroidal tissues (86,87).
R21. Preoperative neck ultrasound for the contralateral lobe
and cervical (central and bilateral) lymph nodes is recom-
mended for all patients undergoing thyroidectomy for ma-
lignant cytologic findings on biopsy—Recommendation B
R22. Routine preoperative use of other imaging studies (CT,
MRI, PET) is not recommended—Recommendation E
Measurement of serum thyroglobulin. There is some evi-
dence that high preoperative concentrations of serum thy-
roglobulin may predict a higher sensitivity for post-opera-
tive surveillance with serum thyroglobulin (88). Evidence
that this impacts patient management or outcomes is not yet
available.
R23. Routine preoperative measurement of serum thy-
roglobulin is not currently recommended—Recommenda-
tion E
What is the appropriate operation for differentiated 
thyroid cancer?
Surgical options for indeterminate biopsies or biopsies di-
agnostic of differentiated thyroid carcinoma. The goal of thy-
roid surgery can include provision of a diagnosis after a non-
diagnostic or indeterminate biopsy, removal of the thyroid
cancer, staging, and preparation for radioactive ablation. Sur-
gical options for thyroid cancer should be limited to lobec-
tomy, near-total thyroidectomy (removal of all grossly visi-
ble thyroid tissue, leaving only a small amount ( 1 gram)
of tissue adjacent to the insertion of the recurrent laryngeal
nerve into the cricothyroid muscle), and total thyroidectomy
(removal of all grossly visible thyroid tissue). Subtotal thy-
roidectomy, leaving more than 1 gram of tissue with the pos-
terior capsule on the involved side, is an inappropriate op-
eration for thyroid cancer (89).
Surgery for a nondiagnostic biopsy, a biopsy suspicious
for papillary cancer, a biopsy suggestive of “follicular neo-
plasm,” including special consideration for patients with other
risk factors. Among solitary thyroid nodules with an inde-
terminate (“suspicious,” “follicular neoplasm,” or Hürthle
cell neoplasm) biopsy, the risk of malignancy is approxi-
mately 20% (90–92). For solitary nodules that are repeatedly
nondiagnostic on biopsy, the risk of malignancy is unknown
but is probably closer to 5%–10% (29).
R24. For patients with an isolated indeterminate solitary nod-
ule who prefer a more limited surgical procedure, thyroid
lobectomy is the recommended initial surgical approach—
Recommendation C
R25. Because of an increased risk for malignancy, total thy-
roidectomy is indicated in patients with large tumors ( 4
cm) when marked atypia is seen on biopsy, when the biopsy
reading is “suspicious for papillary carcinoma,” in patients
with a family history of thyroid carcinoma, and in patients
with a history of radiation exposure (32,93,94). Patients with
bilateral nodular disease or those who prefer to undergo bi-
lateral thyroidectomy to avoid the possibility of requiring a
future surgery on the contralateral lobe should also undergo
total thyroidectomy—Recommendation A
Surgery for a biopsy diagnostic for malignancy. Near-to-
tal or total thyroidectomy is recommended if any of the fol-
lowing are present: the primary thyroid carcinoma is more
than 1–1.5 cm, contralateral thyroid nodules, regional or dis-
tant metastases, patient has a personal history of radiation
therapy to the head and neck, or a first-degree family his-
tory of differentiated thyroid cancer. Older age ( 45 years)
may also be a criterion for recommending near-total or total
thyroidectomy because of higher recurrence rates in this age
group (62,68,69,95,96). Increased extent of primary surgery
may improve survival for high-risk patients (97–99), while
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rates of recurrence are reduced by total- or near-total thy-
roidectomy even among low-risk patients (68,100,101).
R26. For most patients with thyroid cancer, the initial surgi-
cal procedure should be a near-total or total thyroidectomy.
Thyroid lobectomy alone may be sufficient treatment for
small, low-risk, isolated, intrathyroidal papillary carcinomas
in the absence of cervical nodal metastases—Recommenda-
tion A
Lymph node dissection. Regional lymph node metastases
are present at the time of diagnosis in 20%–90% of patients
with papillary carcinoma and a lesser proportion of patients
with other histotypes (75,102). In many cases, these lymph
nodes do not appear abnormal to inspection (103). Bilateral
central (compartment VI) node dissection may improve sur-
vival (compared to historic controls) and reduce the risk for
nodal recurrence (76,103). This central compartment dissec-
tion can be achieved with low morbidity in experienced
hands (104–107).
R27. Routine central-compartment (level VI) neck dissection
should be considered for patients with papillary thyroid car-
cinoma and suspected Hürthle carcinoma. Near-total or to-
tal thyroidectomy without central node dissection may be
appropriate for follicular cancer, and when followed by ra-
dioactive iodine therapy, may provide an alternative ap-
proach for papillary and Hürthle cell cancers—Recommen-
dation B
Lymph nodes in the lateral neck (compartments II–IV) and
posterior triangle (compartment V) may also be involved by
thyroid cancer, most often in papillary and Hürthle cell car-
cinoma (75,108). For those patients in whom nodal disease
is evident clinically, on preoperative ultrasound, or at the
time of surgery, surgical resection may reduce the risk of re-
currence and possibly mortality (102,109,110). Functional
compartmental en-bloc dissection is favored over selective
dissection (berry picking) with limited data suggesting im-
proved mortality (64,111–113).
R28. Lateral neck compartmental lymph node dissection
should be performed for patients with biopsy-proven meta-
static cervical lymphadenopathy detected clinically or by
imaging, especially when they are likely to fail radioactive
iodine treatment based on lymph node size, number, or other
factors, such as aggressive histology of the primary tumor—
Recommendation B
Completion thyroidectomy. Completion thyroidectomy
may be necessary when the diagnosis of malignancy is made
after lobectomy for an indeterminate or nondiagnostic bi-
opsy. Some patients with malignancy may require comple-
tion thyroidectomy to provide complete resection of multi-
centric disease (114), and to allow radioiodine therapy. Most
(115,116) but not all (114) studies of papillary cancer have
observed a higher rate of cancer in the opposite lobe when
multifocal ( 2 foci), as opposed to unifocal, disease is pres-
ent in the ipsilateral lobe. The surgical risks of two-stage 
thyroidectomy (lobectomy followed by completion thy-
roidectomy) are similar to those of a near-total or total thy-
roidectomy (117,118).
R29. Completion thyroidectomy should be offered to those
patients for whom a near-total or total thyroidectomy would
have been recommended had the diagnosis been available
before the initial surgery. This includes all patients with thy-
roid cancer except those with small ( 1 cm), intrathyroidal,
node-negative, low-risk tumors—Recommendation B
R30. Ablation of the remaining lobe with radioactive iodine
has been used as an alternative to completion thyroidectomy
(119). It is unknown whether this approach results in simi-
lar long term outcomes. Consequently, radioactive iodine ab-
lation in lieu of completion thyroidectomy is not recom-
mended—Recommendation E
What is the role of postoperative staging systems and
which should be used?
The role of postoperative staging. Postoperative staging
for thyroid cancer, as for other cancer types, is used: (1) to
permit prognostication for an individual patient with dif-
ferentiated thyroid carcinoma; (2) to tailor decisions re-
garding postoperative adjunctive therapy, including ra-
dioiodine therapy and thyrotropin suppression, to the
patient’s risk for disease recurrence and mortality; (3) to
make decisions regarding the frequency and intensity of fol-
low-up, directing more intensive follow-up towards pa-
tients at highest risk; and (4) to enable accurate communi-
cation regarding a patient between health care professionals.
Staging systems also allow evaluation of differing thera-
peutic strategies applied to comparable groups of patients
in clinical studies.
AJCC/UICC TNM staging. Application of the AJCC/UICC
classification system based on pTNM parameters is recom-
mended for tumors of all types, including thyroid cancer
(67,120), because it provides a useful shorthand method to
describe the extent of the tumor (121) (Table 2). This classi-
fication is also used for hospital cancer registries and epi-
demiologic studies. In thyroid cancer, the AJCC/UICC Stage
does not take account of several additional independent
prognostic variables and may risk misclassification of some
patients. Numerous other schemes have been developed in
an effort to achieve more accurate risk factor stratification,
including CAEORTC, AGES, AMES, U of C, MACIS, OSU,
MSKCC, and NTCTCS systems (61,62,68,98,122–125). These
schemes take into account a number of factors identified as
prognostic for outcome in multivariate analysis of retro-
spective studies, with the most predictive factors generally
being regarded as the presence of distant metastases, the age
of the patient, and the extent of the tumor. These and other
risk factors are weighted differently among these systems 
according to their importance in predicting outcome but 
no scheme has demonstrated clear superiority (125). Never-
theless, each of the schemes allows accurate identification 
of the majority (70%–85%) of patients at low-risk of mor-
tality, allowing the follow-up and management of these 
patients to be less intensive than the higher risk minority,
who may benefit from a more aggressive management 
strategy.
R31. Because of its utility in predicting disease mortality, and
its requirement for cancer registries, AJCC/UICC staging is
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recommended for all patients with differentiated thyroid
cancer. The use of postoperative clinicopathologic staging
systems is also recommended to improve prognostication
and to plan follow-up for patients with differentiated thy-
roid carcinoma—Recommendation B
What is the role of postoperative radioiodine 
remnant ablation?
Postoperative radioiodine remnant ablation is increasingly
being used to eliminate the post-surgical thyroid remnant.
The goals of this treatment are to destroy residual thyroid
tissue in an effort to decrease the risk for recurrent locore-
gional disease and to facilitate long-term surveillance with
whole-body iodine scans and/or stimulated thyroglobulin
measurements (62,63). A number of large, retrospective stud-
ies show a significant reduction in the rates of disease 
recurrence (61,98,99,126) and cause-specific mortality
(98,99,126–128). However, other similar studies show no
such benefit, at least among the majority of patients with
papillary thyroid carcinoma, who are at the lowest risk for
mortality (68,101,128–131). In those studies that show bene-
fit, the advantage appears to be restricted to patients with
larger tumors ( 1.5 cm), or with residual disease after sur-
gery, while lower risk patients do not show evidence for ben-
efit (68,98,132). No prospective studies have been performed
to address this question (128).
R32. Radioiodine ablation is recommended for patients with
stages III and IV disease (AJCC sixth edition; Table 2), all pa-
tients with stage II disease younger than age 45 years and
most patients with stage II disease 45 years or older, and se-
lected patients with stage I disease, especially those with
multifocal disease, nodal metastases, extrathyroidal or vas-
cular invasion, and/or more aggressive histologies—Rec-
ommendation B
How should patients be withdrawn from thyroid hormone
prior to radioiodine ablation?
Remnant ablation (as well as subsequent monitoring for
thyroid cancer persistence/recurrence using radioiodine
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TABLE 2. TNM CLASSIFICATION SYSTEM FOR DIFFERENTIATED THYROID CARCINOMA
Definition
T1 Tumor diameter 2 cm or smaller
T2 Primary tumor diameter  2 to 4 cm
T3 Primary tumor diameter  4 cm limited to the thyroid or with minimal extrathyroidal extension
T4a Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx,
trachea, esophagus, or recurrent laryngeal nerve
T4b Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels
TX Primary tumor size unknown, but without extrathyroidal invasion
NO No metastatic nodes
N1a Metastases to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)
N1b Metastasis to unilateral, bilateral, contralateral cervical or superior mediastinal mode metastases
NX Nodes not assessed at surgery
MO No distant metastases
M1 Distant metastases
MX Distant metastases not assessed
Stages
Patient age  45 years Patient aged 45 years or older
Stage I Any T, any N, MO T1, NO, MO
Stage II Any T, any N, M1 T2, NO, MO












IVB T4b, Any N, MO
Stage
IVC Any T, Any N, M1
Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois.
The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002). Published by Springer-Verlag, New York, Inc.
whole-body scans (WBS) and/or serum thyroglobulin mea-
surement) requires TSH stimulation. No controlled studies
have been performed to assess adequate levels of endoge-
nous TSH for optimal ablation therapy or follow-up testing.
Noncontrolled studies suggest that a TSH of more than 30
mU/L is associated with increased radioiodine uptake in tu-
mors (133), while studies using single-dose exogenous TSH
suggest maximal thyrocyte stimulation at TSH levels be-
tween 51–82 mU/L (134,135). Endogenous TSH elevation can
be achieved by two basic approaches to thyroid hormone
withdrawal, stopping levothyroxine (LT4) and switching to
levotriiodothyronine (LT3) for 2–4 weeks followed by with-
drawal of triiodothyronine (T3) for 2 weeks, or discontinua-
tion of LT4 for 3 weeks without use of T3. Both methods of
preparation can achieve serum TSH levels greater than 30
mU/L in greater than 90% of patients (135–144). These two
approaches have not been directly compared for efficiency
of patient preparation (efficacy of ablation, iodine uptake,
thyroglobulin levels, disease detection, or symptoms). Other
preparative approaches have been proposed, but have not
been validated by other investigators (145,146).
R33. Patients undergoing radioiodine therapy or diagnostic
testing can be prepared by LT4 withdrawal for at least 3 weeks
or T3 treatment for 2–4 weeks and T3 withdrawal for 2 weeks
with measurement of serum TSH to determine timing of test-
ing or therapy (TSH  30 mU/L)—Recommendation B
Should radioiodine scanning be performed before
radioiodine ablation?
Radioiodine WBS provides information on the presence of
iodine-avid thyroid tissue, which may represent the normal
thyroid remnant or the presence of residual disease in the
postoperative setting. In the presence of a large thyroid rem-
nant, the scan is dominated by uptake within the remnant,
potentially masking the presence of extrathyroidal disease
within locoregional lymph nodes, the upper mediastinum or
even at distant sites, reducing the sensitivity of disease de-
tection (147). Furthermore, there is an increasing trend to
avoid pretherapy radioiodine scans altogether because of
concerns over 131I-induced stunning of thyroid cancer (148).
Stunning is defined as a reduction in uptake of the 131I ther-
apy dose induced by a pretreatment diagnostic dose. Stun-
ning occurs most prominently with higher doses (5–10 mCi)
of 131I (149), with increasing time between the diagnostic
dose and therapy (150), and is not visually appreciated at
lower doses (1–3 mCi). However, the accuracy of low-dose
131I scans has been questioned, and some have reported
quantitatively the presence of stunning below the threshold
of visual detection (151). Although comparison studies show
excellent concordance between 123I and 131I for tumor de-
tection, optimal 123I activity and time to scan after 123I ad-
ministration is not known (152). Furthermore, 123I is expen-
sive, is not universally available, its short half life (t1/2  13 
hours) makes handling this isotope more difficult (153), and
stunning may also occur though to a lesser degree than with
131I (150). Determination of the thyroid bed uptake can be
achieved using 10–100 Ci 131I.
R34. Pretherapy scans and/or measurement of thyroid bed
uptake may be useful when the extent of the thyroid rem-
nant cannot be accurately ascertained from the surgical re-
port or neck ultrasonography, or when the results would al-
ter either the decision to treat or the activity of radioiodine
that is administered. If performed, pretherapy scans should
utilize low-dose 131I (1–3 mCi) or 123I—Recommendation C
What activity of 131I should be used for remnant ablation?
Successful remnant ablation is usually defined as an ab-
sence of visible radioiodine uptake on a subsequent diag-
nostic radioiodine scan. Activities between 30 and 100 mCi
of 131I generally show similar rates of successful remnant ab-
lation (154–157), although there is a trend toward higher suc-
cess rates with higher activities (158).
R35. The minimum activity (30–100 mCi) necessary to
achieve successful remnant ablation should be chosen, par-
ticularly for low-risk patients—Recommendation B
R36. If residual microscopic disease is suspected or docu-
mented, or if there is a more aggressive tumor histology (e.g.
tall cell, insular, columnar cell carcinoma) , then higher activ-
ities (100– 200 mCi) may be appropriate—Recommendation C
Can recombinant human thyrotropin (Thyrogen™) be
used in lieu of thyroxine withdrawal for remnant ablation?
There is limited experience with the use of recombinant
human thyrotropin (rhTSH) in radioiodine ablation of post-
surgical thyroid remnants. Some patients, unable to tolerate
hypothyroidism or unable to generate an elevated TSH, 
have undergone successful remnant ablation with rhTSH
(159,160). Successful remnant ablation with 30 mCi 131I was
equivalent after thyroxine withdrawal compared to rhTSH
stimulation when the thyroxine therapy was stopped 1 day
prior to the rhTSH injections and restarted the day after 131I
therapy (161). rhTSH is not approved in the United States
for this indication, but it is approved in Europe.
R37. Remnant ablation can be performed following thyrox-
ine withdrawal or rhTSH stimulation—Recommendation Ba
Is a low-iodine diet necessary before remnant ablation?
The efficacy of radioactive iodine depends on the radia-
tion dose delivered to the thyroid tissue (162). Low-iodine
diets ( 50 g/d of dietary iodine) have been recommended
prior to radioiodine therapy (162–164), to increase the effec-
tive radiation dose. Measurement of iodine excretion may be
a useful way to identify patients whose iodine intake could
interfere with radioiodine remnant ablation (164).
R38. A low-iodine diet for 1–2 weeks is recommended for
patients undergoing radioiodine remnant ablation, particu-
larly for those patients with high iodine intake—Recom-
mendation B
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aNote: Because of varying degrees of involvement with Genzyme
Corporation, the manufacturer of rhTSH (Thyrogen), the following
authors recused themselves from the discussion of this recommen-
dation: Bryan Haugen, M.D.; Richard Kloos, M.D.; Ernest Mazza-
ferri, M.D.; Steven Sherman, M.D.; and R. Michael Tuttle, M.D.
Should a posttherapy scan be performed after 
remnant ablation?
Posttherapy whole body iodine scanning is typically con-
ducted approximately 1 week after radioactive iodine ther-
apy to visualize metastases. Additional metastatic foci have
been reported in 10%–26% of patients scanned after high-
dose radioiodine treatment compared to the diagnostic scan
(165,166). The new abnormal uptake was found most often
in the neck, lungs and mediastinum, and the newly discov-
ered disease altered the disease stage in approximately 10%
of the patients, affecting clinical management in 9%–15%
(165–167).
R39. A posttherapy scan is recommended after radioiodine
remnant ablation. This is typically done 5–8 days after the
therapeutic dose is administered, although published data
supporting this time interval are lacking—Recommendation
B 
What is the role of TSH suppression therapy?
Differentiated thyroid cancer expresses the thyrotropin re-
ceptor on the cell membrane, and responds to TSH stimula-
tion by increasing the expression of several thyroid-specific
proteins (thyroglobulin, sodium iodide symporter) and by
increasing the rates of cell growth. Suppression of TSH, us-
ing supraphysiologic doses of LT4, is used commonly to treat
patients with thyroid cancer in an effort to decrease the risk
of recurrence (73,168). A recent meta-analysis supported the
efficacy of TSH suppression therapy in preventing major ad-
verse clinical events (relative risk [RR]  0.73; confidence in-
terval [CI]  0.60–0.88; p  0.05) (168).
What is the appropriate degree of initial 
TSH suppression?
Retrospective studies have demonstrated that TSH sup-
pression to below 0.1 mU/L may improve outcomes in high-
risk patients with thyroid cancer (73,169), although no such
evidence of benefit has been documented in low-risk pa-
tients. Adverse effects of TSH suppression may include the
known consequences of subclinical thyrotoxicosis, including
exacerbation of angina in patients with ischemic heart dis-
ease, increased risk for atrial fibrillation, and increased risk
of osteoporosis in postmenopausal women (170).
R40. Initial thyrotropin suppression to below 0.1 mU/L is
recommended for high-risk patients with thyroid cancer,
while maintenance of the TSH at or slightly below the lower
limit of normal (0.1–0.5 mU/L) is appropriate for low-risk
patients—Recommendation B
Is there a role for adjunctive external beam irradiation 
or chemotherapy?
External beam irradiation. External beam irradiation is
used infrequently in the management of thyroid cancer ex-
cept as a palliative treatment for locally advanced, otherwise
unresectable disease (171). There are reports of responses
among patients with locally advanced disease (172,173), and
improved relapse-free and cause-specific survival (174). It re-
mains unknown whether external beam radiation might re-
duce the risk for recurrence in the neck after adequate pri-
mary surgery and/or radioiodine treatment.
R41. The use of external beam irradiation should be consid-
ered in patients over age 45 with grossly visible extrathy-
roidal extension at the time of surgery and a high likelihood
of microscopic residual disease, and for those patients with
gross residual tumor in whom further surgery or radioactive
iodine would likely be ineffective—Recommendation B
Chemotherapy. There are no data to support the use of ad-
junctive chemotherapy in the management of differentiated
thyroid cancer. Doxorubicin (adriamycin) may act as a radi-
ation sensitizer in some tumors of thyroid origin (175,176),
and could be considered for patients with locally advanced
disease undergoing external beam radiation.
R42. There is no role for the routine adjunctive use of che-
motherapy in patients with differentiated thyroid cancer—
Recommendation F
Differentiated Thyroid Cancer: Long-Term
Management
What are the appropriate features of long-term manage-
ment?
Accurate surveillance for possible recurrence in patients
thought to be free of disease is a major goal of long-term fol-
low up. Tests with high negative predictive value allow iden-
tification of patients unlikely to experience disease recur-
rence, so that less aggressive management strategies can be
used that may be more cost effective and safe. Similarly, pa-
tients with a higher risk of recurrence are monitored more
aggressively, based on the admittedly unproven premise,
that early detection of recurrent disease offers the best op-
portunity for effective treatment. Patients with persistent or
recurrent disease are offered treatment to cure or to delay
future morbidity or mortality. In the absence of such options,
therapies to palliate by substantially reducing tumor burden
or preventing tumor growth are utilized, with special atten-
tion paid to tumor-threatening critical structures.
Follow-up is different for patients at low, intermediate, and
at high risk of having persistent or recurrent disease. AJCC-
IUCC staging was developed to predict risk for death, not
recurrence. For assessment of risk of recurrence, a three level
stratification can be used. Low-risk patients have the fol-
lowing characteristics after initial surgery and remnant ab-
lation: no local or distant metastases; all macroscopic tumor
has been resected, there is no tumor invasion of locoregional
tissues or structures, the tumor does not have aggressive his-
tology (e.g., tall cell, insular, columnar cell carcinoma) or vas-
cular invasion, and, if 131I is given, there is no 131I uptake
outside the thyroid bed on the first posttreatment whole-
body radioiodine scan (RxWBS) (177–179). Intermediate-risk
patients have microscopic invasion of tumor into the perithy-
roidal soft tissues at initial surgery or tumor with aggressive
histology or vascular invasion (180–182). High-risk patients
have macroscopic tumor invasion, incomplete tumor resec-
tion, distant metastases, or 131I uptake outside the thyroid
bed on the post-treatment scan done after thyroid remnant
ablation (183,184).
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What is the appropriate method of following patients after
surgery with or without remnant ablation?
Criteria for absence of persistent tumor. In patients who
have undergone total or near-total thyroidectomy and thy-
roid remnant ablation, disease free status comprises all of the
following: no clinical evidence of tumor, no imaging evi-
dence of tumor (no uptake outside the thyroid bed on the
initial posttreatment whole body scan, on a recent diagnos-
tic scan or neck ultrasound), and undetectable serum thy-
roglobulin levels during TSH suppression and stimulation
in the absence of interfering antibodies (Figs. 2 and 3).
What is the role of serum thyroglobulin assays in the
follow-up of differentiated thyroid cancer?
Measurement of serum thyroglobulin levels is an impor-
tant modality to monitor patients for residual or recurrent
disease. Serum thyroglobulin has a high degree of sensitiv-
ity and specificity to detect thyroid cancer, especially after
total thyroidectomy and remnant ablation, with the highest
degrees of sensitivity noted after thyroid hormone with-
drawal or stimulation using recombinant human thyrotropin
(rhTSH) (185). Serum thyroglobulin measurements obtained
during thyroid hormone suppression of TSH may fail to
identify patients with relatively small amounts of resid-
ual tumor (177,186). Conversely, even TSH-stimulated thy-
roglobulin measurement may fail to identify patients with
clinically significant tumor, because of antithyroglobulin an-
tibodies, or less commonly, defective or absent production
and secretion of immunoreactive thyroglobulin by tumor
cells (187). Thyroglobulin levels should be interpreted in
light of the pretest probability of clinically significant resid-
ual tumor. An aggressive or poorly differentiated tumor may
be present despite low basal or stimulated thyroglobulin; in
contrast, a minimally elevated stimulated thyroglobulin may
occur in patients at low risk for clinically significant mor-
bidity (188).
Initial follow-up for low-risk patients (approximately 85%
of postoperative patients) who have undergone total or near-
total thyroidectomy and 131I remnant ablation should be
based mainly on TSH-suppressed thyroglobulin and cervi-
cal ultrasound, followed by TSH-stimulated serum thy-
roglobulin measurements if the TSH-suppressed thyroglob-
ulin testing is undetectable (177,186).
Approximately 20% of patients who are clinically free of
disease with serum thyroglobulin levels less than 1 ng/mL
during thyroid hormone suppression of TSH (186) will have
a serum thyroglobulin level greater than 2 ng/mL after
rhTSH or thyroid hormone withdrawal. In approximately
one third of this group, persistent tumor can be identified
on imaging studies. There is good evidence that a thy-
roglobulin cutoff level above 2 ng/mL after rhTSH stimula-
tion is highly sensitive in identifying patients with persistent
tumor (186,189–194). However, the results of serum thy-
roglobulin measurements made on the same serum speci-
men differ among laboratories (88). Therefore, the thy-
roglobulin cutoff may differ slightly among medical centers
and laboratories. Furthermore, the clinical significance of
minimally detectable thyroglobulin levels is unclear, espe-
cially if only detected after TSH stimulation.
The presence of antithyroglobulin antibodies, which occur
in approximately 25% of thyroid cancer (195) patients and
10% of the general population (196), will falsely lower serum
thyroglobulin determinations in immunometric assays (197).
The use of recovery assays for this purpose is controversial
(184,198). Serial serum antithyroglobulin antibody measure-
ments may serve as an imprecise surrogate marker of resid-
ual normal thyroid tissue or tumor (198,199). Serum thy-
roglobulin measurements are less sensitive in patients with
small cervical lymph node metastases or less differentiated
tumor (184,200). A rising unstimulated or stimulated serum
thyroglobulin may indicate disease that is likely to become
clinically apparent (201,202).
R43. Serum thyroglobulin should be measured every 6–12
months by an immunometric assay, ideally in the same lab-
oratory and using the same assay, during follow-up of pa-
tients with differentiated thyroid carcinoma who have 
undergone total or near-total thyroidectomy and thyroid
remnant ablation. Thyroglobulin antibodies should be quan-
titatively assessed with every measurement of serum thy-
roglobulin—Recommendation A
R44. Periodic serum thyroglobulin measurements should be
considered during follow-up of patients with differentiated
thyroid carcinoma who have undergone less than total thy-
roidectomy, and in patients who have had a total thy-
roidectomy but not radioiodine ablation. The cutoff levels to
detect tumor during TSH suppression or stimulation are not
known, but unstimulated or stimulated levels greater than 2
ng/mL that increase over time may represent recurrent dis-
ease—Recommendation C
R45. In low risk patients who have had remnant ablation and
negative cervical ultrasound and TSH-suppressed thy-
roglobulin 6 months after treatment, serum thyroglobulin
should be measured after thyroxine withdrawal or rhTSH
stimulation approximately 12 months after the ablation to
verify absence of disease. The timing or necessity of subse-
quent stimulated testing is uncertain for those found to be
free of disease—Recommendation A
What are the roles of diagnostic whole-body radioiodine
scans, ultrasound, and other imaging techniques during
follow-up of differentiated thyroid cancer?
Diagnostic whole-body radioiodine scans. There are two
main issues that affect the use of diagnostic whole body ra-
dioiodine scans (DxWBS) during follow-up: stunning (de-
scribed above) and accuracy. A DxWBS is most useful dur-
ing follow-up when there is little or no remaining normal
thyroid tissue. Disease not visualized on the DxWBS, re-
gardless of the activity of 131I used, may occasionally be vi-
sualized on the RxWBS images done after larger, therapeu-
tic amounts of 131I (186,203–206). After radioiodine ablation,
subsequent DxWBS have low sensitivity and are usually not
necessary in low-risk patients who are clinically free of re-
sidual tumor and have an undetectable serum thyroglobu-
lin level during thyroid hormone suppression of serum TSH
and negative cervical ultrasound (177,183,186,205,207).
R46. After the first RxWBS performed after radioiodine rem-
nant ablation, low-risk patients with negative TSH-stimu-
lated thyroglobulin and cervical ultrasound do not require
routine DxWBS during follow-up—Recommendation A
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FIG. 2. Algorithm for initial follow-up of patients with differentiated thyroid carcinoma. aEBRT is external beam radio-
therapy. The usual indication for EBRT is macroscopic unresectable tumor in a patient older than 45 years. bNeck ultra-
sonography of operated cervical compartments is often compromised for several months after surgery. cTg is thyroglobu-
lin with antithyroglobulin antibody measurement; serum Tg is usually measured by immunometric assay and may be falsely
elevated for several weeks by injury from surgery or by heterophile antibodies, although a very high serum Tg level after
surgery usually indicates residual disease. dSome clinicians suspect residual disease when malignant lymph nodes, or tu-
mors with aggressive histologies (as defined in the text) have been resected, or when there is a microscopically positive
margin of resection. erhTSH is recombinant human thyrotropin, which is not Food and Drug Administration (FDA)-ap-
proved in the United States for preparing patients for therapy, but was approved in 2005 for remnant ablation in Europe,
and is administered as follows: 0.9 mg rhTSH intramuscularly on 2 consecutive days, followed by 131I therapy on third day.
fTHW is levothyroxine and/or triiodothyronine withdrawal. gSee text for exceptions regarding remnant ablation. DxWBS
(diagnostic whole body scintigraphy) is not usually necessary at this point, but may be performed if the outcome will change
the decision to treat with radioiodine and/or the amount of administered activity. hRxWBS is posttreatment whole-body
scan done 5 to 8 days after therapeutic 131I administration. (Modified from J Nucl Med, 46:1079–1088, 2005. Reprinted with
permission.)
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FIG. 3. Longer term follow-up of patients with differentiated thyroid carcinoma. iTgAb is antithyroglobulin antibody usu-
ally measured by immunometric assay. jHeterophile antibodies may be a cause of falsely elevated serum Tg levels. (Preiss-
ner CM, Dodge LA, O’Kane DJ, Singh RJ, Grebe SK 2005 Prevalence of heterophilic antibody interference in eight auto-
mated tumor marker immunoassays. Clin Chem 51:208–210; Preissner CM, O’Kane DJ, Singh RJ, Morris JC, Grebe SK 2003
Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab
88:3069–3074.) The use of heterophile blocking tubes or heterophile blocking reagents have reduced, but not completely
eliminated this problem. Tg that rises with thyrotropin (TSH) stimulation and falls with TSH suppression is unlikely to re-
sult from heterophile antibodies. kSee text concerning further information regarding levels of Tg at which therapy should
be considered. lTg radioimmunoassay (RIA) may be falsely elevated or suppressed by TgAb. Tg results following TSH stim-
ulation with recombinant human thyrotropin (rhTSH) or thyroid hormone withdrawal are invalidated by TgAb in the serum
even when Tg is measured by most RIA tests. TgAb levels often decline to undetectable levels over years following sur-
gery (Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A 2003 Disappearance
of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139:346–351). A rising level
of TgAb may an early indication of recurrent disease (Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB,
Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thy-
roglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol
Metab 83:1121–1127). mSee text for decision regarding surgery versus medical therapy, and surgical approaches to locore-
gional metastases. Fine-needle aspiration confirmation of malignancy is generally advised. Preoperative chest computed to-
mography (CT) is recommended as distant metastases may change management. (Modified from J Nucl Med, 46:1079–1088,
2005. Reprinted with permission.)
R47. DxWBS 6–12 months after remnant ablation may be of
value in the follow-up of patients with high or intermediate
risk of persistent disease, but should be done with low dose
131I or 123I—Recommendation C
Cervical ultrasonography. Cervical ultrasonography is
highly sensitive in the detection of cervical metastases in pa-
tients with differentiated thyroid cancer (208). Cervical
metastases occasionally may be detected by neck ultra-
sonography even when TSH-stimulated serum thyroglobu-
lin levels remain undetectable (200).
R48. After surgery, cervical ultrasound to evaluate the thyroid
bed and central and lateral cervical nodal compartments
should be performed at 6 and 12 months and then annually
for at least 3–5 years, depending on the patients’ risk for re-
current disease and thyroglobulin status—Recommendation B
What is the role of thyroxine suppression in long-term
follow-up of differentiated thyroid cancer?
A meta-analysis has suggested an association (168) be-
tween thyroid hormone suppression therapy and reduction
of major adverse clinical events. The appropriate degree of
TSH suppression by LT4 is still unknown. One study found
that a constantly suppressed TSH ( 0.05 U/mL) was as-
sociated with a longer relapse-free survival than when serum
TSH levels were always 1 U/mL or greater, and that the
degree of TSH suppression was an independent predictor of
recurrence in multivariate analysis (169). Conversely, an-
other large study found that disease stage, patient age, and
131I therapy independently predicted disease progression,
but that the degree of TSH suppression did not (73). A third
study showed that during LT4 therapy the mean thyroglob-
ulin levels were significantly higher when TSH levels were
normal than when TSH levels were suppressed ( 0.5
mU/L) but only in patients with local or distant relapse (209).
R49. In patients with persistent disease, the serum TSH
should be maintained below 0.1 mU/L indefinitely in the ab-
sence of specific contraindications—Recommendation B
R50. In patients who are clinically free of disease but who
presented with high risk disease, consideration should be
given to maintaining TSH suppressive therapy to achieve
serum TSH levels of 0.1 to 0.5 mU/L for 5–10 years—Rec-
ommendation C
R51. In patients free of disease, especially those at low risk
for recurrence, the TSH may be kept within the low normal
range (0.3 to 2 mU/L)—Recommendation C
What is the most appropriate management of patients
with metastatic disease?
Metastases discovered during follow-up are likely mani-
festations of persistent disease that has survived initial treat-
ment, and are often incurable by additional 131I treatment.
Some patients will have a reduction in tumor burden with
additional treatments that may offer a survival or palliative
benefit (204,210–212).
The preferred hierarchy of treatment for metastatic dis-
ease (in order) is surgical excision of locoregional disease in
potentially curable patients, 131I therapy, external beam ra-
diation, watchful waiting with patients with stable asymp-
tomatic disease, and experimental chemotherapy trials. Ex-
perimental trials may be tried before external beam radiation
in special circumstances, in part because of the morbidity of
external beam radiation and its relative lack of efficacy. A
small fraction of patients may benefit from radiofrequency
ablation (213), ethanol ablation (214), or chemoembolization
(215).
Surgical management of locoregional metastases. Surgery
is favored for locoregional (i.e., cervical lymph nodes and/or
soft tissue tumor in the neck) recurrences, when distant
metastases are not present. Approximately one third to one
half of patients may become free of disease in short-term fol-
low-up (216). It is not clear that treatment of locoregional
disease is beneficial in the setting of untreatable distant
metastases, except for possible palliation of symptoms or
prevention of airway or aero-digestive obstruction. Impal-
pable metastatic lymph nodes, visualized on ultrasound or
other anatomic imaging modality, have survived initial 131I
therapy and should be considered for resection. Most sur-
geons endorse complete ipsilateral compartmental dissection
of involved compartments with persistent/recurrent disease
while sparing vital structures (e.g., ipsilateral central neck
dissection [level VI], or modified neck dissection [levels II–V
sparing the spinal accessory nerve, the internal jugular vein,
and sternocleidomastoid muscle]) (217) as opposed to berry
picking or selective lymph node resection procedures or eth-
anol ablation (214), because microscopic lymph node metas-
tases are commonly more extensive than would appear from
imaging studies alone (112,218,219).
R52. Patients with persistent/recurrent disease confined to
the neck should undergo complete ipsilateral or central com-
partmental dissection of involved compartments while spar-
ing vital structures—Recommendation B
Surgical management of aero-digestive invasion. For tu-
mors that invade the upper aero-digestive tract, surgery
combined with additional therapy such as 131I and/or ex-
ternal beam radiation is generally advised (220,221). Patient
outcome is related to complete resection of all gross disease
with the preservation of function, with techniques ranging
from shaving tumor off the trachea or esophagus for super-
ficial invasion, to more aggressive techniques when the tra-
chea is more deeply invaded (e.g., direct intraluminal inva-
sion) including tracheal resection and anastomosis (222–224)
or esophagopharyngectomy. Patients who are not curable
may undergo less aggressive local treatment. Tracheal stents
and tracheotomy can improve quality of life. Laser therapy
is indicated in cases of asphyxia or significant hemoptysis
and as a preliminary step prior to subsequent radical or pal-
liative treatments (221).
R53. When technically feasible, surgery for aero-digestive
disease is recommended in combination with radioiodine
and/or external beam radiotherapy—Recommendation B
Radioiodine therapy for locoregional or distant metastatic
disease. For regional nodal metastases discovered on
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DxWBS, radioiodine is usually used, although surgery is typ-
ically used in the presence of bulky disease or disease
amenable to surgery found on anatomic imaging such as ul-
trasound, CT scanning or MRI. Radioiodine is also used ad-
junctively after surgery for regional nodal disease or aero-
digestive invasion if residual disease is present or suspected.
Methods of administering 131I for locoregional or metasta-
tic disease. Despite the apparent effectiveness of 131I ther-
apy in many patients, the optimal therapeutic activity re-
mains uncertain and controversial (225). There are three
approaches to 131I therapy: empiric fixed amounts, therapy
determined by the upper bound limit of blood and body
dosimetry, and quantitative tumor dosimetry (226). Dosi-
metric methods are often reserved for patients with distant
metastases or unusual situations such as renal failure or
when therapy with rhTSH stimulation is deemed necessary.
Comparison of outcome among these methods from pub-
lished series is difficult (227). No prospective randomized
trial to address the optimal therapeutic approach has been
published. Arguments in favor of higher activities cite a pos-
itive relationship between the total 131I uptake per tumor
mass and outcome (141), while others have not confirmed
this relationship (227,228).
R54. In the treatment of locoregional or metastatic disease,
no recommendation can be made about the superiority of
one method of radioiodine administration over another (em-
piric high dose versus blood or body dosimetry)—Recom-
mendation I
rhTSH in the management of recurrent or metastatic dis-
ease. No randomized trial comparing thyroid hormone
withdrawal therapy to rhTSH-mediated therapy has been re-
ported, despite a growing body of nonrandomized studies
regarding this use (229–237). The use of rhTSH does not elim-
inate and may even increase the possibility of rapid swelling
of metastatic lesions (234,238–240). Many of these case re-
ports and series report disease stabilization or improvement
in some patients after rhTSH-mediated 131I therapy.
R55. There are currently insufficient outcome data to rec-
ommend rhTSH-mediated therapy for all patients with met-
astatic disease being treated with 131I—Recommendation D
R56. rhTSH-mediated therapy may be indicated in selected
patients with underlying comorbidities making iatrogenic
hypothyroidism potentially risky, in patients with pituitary
disease who are unable to raise their serum TSH, or in pa-
tients in whom a delay in therapy might be deleterious—
Recommendation C
The use of lithium in 131I therapy. Lithium inhibits iodine
release from the thyroid without impairing iodine uptake,
thus enhancing 131I retention in normal thyroid and tumor
cells (241). One study (242) found that lithium increased the
estimated 131I radiation dose in metastatic tumors an aver-
age of more than twofold, but primarily in those tumors that
rapidly cleared iodine (242).
R57. Because there are no outcome data that demonstrate a
better outcome of patients treated with 131I in the setting of
lithium therapy, the committee cannot recommend for or
against its use—Recommendation I
Treatment of distant metastatic disease. The overall ap-
proach to treatment of distant metastatic thyroid cancer is
based upon the following observations and oncologic prin-
ciples:
1. Morbidity and mortality are increased in patients with
distant metastases, but individual prognosis depends
upon factors including distribution and number of sites
of metastasis (e.g., brain, bone, lung), tumor burden, and
age at diagnosis of metastases (212,237,243–249).
2. Improved survival is associated with responsiveness to
surgery and/or radioiodine (212,237,243–249).
3. In the absence of demonstrated survival benefit, certain
interventions can provide significant palliation or reduce
morbidity (216,250–252).
4. In the absence of improved survival, palliative benefit or
reduced potential morbidity, the value of empiric thera-
peutic intervention is significantly limited by the poten-
tial for toxicity.
5. Treatment of a specific metastatic area must be consid-
ered in light of the patient’s performance status and other
sites of disease (e.g., 5%–20% of patients with distant
metastases die from progressive cervical disease (249,253).
6. Longitudinal reevaluation of patient status and continu-
ing reassessment of potential benefit and risk of inter-
vention is required.
7. The overall poor outcome of patients with radiographi-
cally evident or symptomatic metastases that do not re-
spond to radioiodine, the complexity of multidisciplinary
treatment considerations and the availability of prospec-
tive clinical trials should encourage the clinician to refer
such patients to tertiary centers with particular expertise.
Treatment of pulmonary metastases. In the management
of the patient with pulmonary metastases, key criteria for
therapeutic decisions include size of metastatic lesions
(macronodular typically detected by chest radiography; mi-
cronodular typically detected by CT; lesions beneath the res-
olution of CT); avidity for radioiodine and, if applicable, re-
sponse to prior radioiodine therapy; and stability (or lack
thereof) of metastatic lesions. Pulmonary pneumonitis and
fibrosis are rare complications of high dose radioactive io-
dine treatment. Dosimetry studies with a limit of 80 mCi
whole-body retention at 48 hours and 200 cGy to the red
bone marrow should be considered in patients with diffuse
131I pulmonary uptake (254). If pulmonary fibrosis is sus-
pected, then appropriate periodic pulmonary function test-
ing and consultation should be obtained. The presence of
pulmonary fibrosis may limit the ability to further treat met-
astatic disease with radioiodine.
R58. Pulmonary micrometastases should be treated with ra-
dioiodine therapy, repeated every 6–12 months as long as
disease continues to respond, as the highest rates of 
complete remission are reported in these subgroups
(243,248,255)—Recommendation A
R59. The selection of radioiodine activity to administer for
pulmonary micrometastases can be empiric (100–300 mCi)
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or estimated by dosimetry to limit whole body retention to
80 mCi at 48 hours and 200 cGy to the red bone marrow—
Recommendation C
Macronodular pulmonary metastases may also be treated
with radioiodine if demonstrated to be iodine avid. How many
doses of radioiodine to give and how often to give it is a de-
cision that must be individualized based on the disease re-
sponse to treatment, the rate of disease progression in between
treatments, age of the patient, size of the lesion, and pres-
ence/absence of other metastatic lesions and the availability of
other treatment options including clinical trials (243,248)
R60. Radioiodine-avid macronodular metastases should be
treated with radioiodine, and treatment repeated when ob-
jective benefit is demonstrated (decrease in the size of the le-
sions, decreasing thyroglobulin), but complete remission is
not common and survival remains poor. The selection of ra-
dioiodine activity to administer can be made empirically
(100–300 mCi) or estimated by dosimetry to limit whole body
retention to 80 mCi at 48 hours and 200 cGy to the red bone
marrow—Recommendation B
Nonradioiodine avid pulmonary disease. In one study, ad-
ministration of 200–300 mCi of radioiodine to 10 patients
with pulmonary macrometastases who had negative 3 mCi
diagnostic scans was associated with a fivefold increase in
the median TSH-suppressed thyroglobulin, and death was
reported in several patients within 4 years of treatment (256).
Although not specifically limited to pulmonary lesions, pa-
tients with increasing volumes of 18-fluorodeoxyglucose
(FDG)-avid disease seen on positron-emission tomograpy
(PET) scans were less likely to respond to radioiodine and
more likely to die during a 3-year follow-up compared with
FDG-negative patients (257). One study found that radioio-
dine therapy of metastatic lesions that were positive on FDG-
PET scanning was of no benefit (258). In other studies of
FDG-PET imaging, however, insufficient details exist in pa-
tients known to have pulmonary metastases to assess the
utility of this modality to predict treatment response or prog-
nosis (259). Traditional cytotoxic chemotherapeutic agents
such as doxorubicin and cisplatin, are generally associated
with no more than 25% partial response rates, and complete
remission has been rare (260).
R61. Evidence of benefit of routine treatment of nonradioio-
dine avid pulmonary metastases is insufficient to recom-
mend any specific systemic therapy—Recommendation I
R62. For many patients, metastatic disease is slowly pro-
gressive and patients can often be followed conservatively
on TSH-suppressive therapy with minimal evidence of ra-
diographic or symptomatic progression. For selected pa-
tients, however, other treatment options need to be consid-
ered, such as metastasectomy, endobronchial laser ablation,
or external beam radiation for palliation of symptomatic in-
trathoracic lesions (e.g., obstructing or bleeding endo-
bronchial masses), and pleural or pericardial drainage for
symptomatic effusions. Referral for participation in clinical
trials should be considered—Recommendation C
Treatment of bone metastases. In the management of the
patient with bone metastases, key criteria for therapeutic de-
cisions include risk for pathologic fracture, particularly in a
weight-bearing structure; risk for neurologic compromise
from vertebral lesions; presence of pain; avidity of radioio-
dine uptake; and potential significant marrow exposure from
radiation arising from radioiodine-avid pelvic metastases.
R63. Complete surgical resection of isolated symptomatic
metastases has been associated with improved survival and
should be considered, especially in patients less than 45 years
old (212,246)—Recommendation B
R64. Radioiodine therapy of iodine-avid bone metastases has
been associated with improved survival and should be used
(212,248). The radioiodine activity administered can be given
empirically (150–300 mCi) or estimated by dosimetry (140)—
Recommendation B
R65. When skeletal metastatic lesions arise in locations where
acute swelling may produce severe pain, fracture, or neuro-
logic complications, external radiation and the concomi-
tant use of glucocorticoids to minimize potential TSH-in-
duced and/or radiation related tumor expansion should be
strongly considered (261)—Recommendation C
R66. Painful lesions that cannot be resected can also be
treated by several options individually or in combination, in-
cluding: radioiodine, external beam radiotherapy; intra-ar-
terial embolization (215,262), radiofrequency ablation (263),
periodic pamidronate or zoledronate infusions (with moni-
toring for development of possible osteonecrosis) (252), or
bone-seeking radiopharmaceuticals such as strontium-89 or
samarium-153 (264). While many of these modalities have
been shown to relieve bone pain in cancer, they have not
necessarily been reported to have been used in patients with
thyroid cancer—Recommendation C
R67. Evidence is insufficient to recommend treatment of
asymptomatic, non-radioiodine responsive, stable lesions
that do not threaten nearby critical structures—Recommen-
dation I
Treatment of brain metastases. Brain metastases typically
occur in older patients with more advanced disease at pre-
sentation, and are associated with a poor prognosis (237).
Surgical resection and external beam radiotherapy tradi-
tionally have been the mainstays of therapy (237,265). There
are few data showing efficacy of radioiodine.
R68. Complete surgical resection of central nervous system
(CNS) metastases should be considered regardless of ra-
dioiodine avidity, as it is associated with significantly longer
survival—Recommendation B
R69. CNS lesions that are not amenable to surgery should be
considered for external beam irradiation. Often very targeted
approaches (such as radiosurgery) are employed to limit the
radiation exposure of the surrounding brain tissue. Whole-
brain and spine irradiation could be considered if multiple
metastases are present—Recommendation C
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R70. If CNS metastases do concentrate radioiodine, then ra-
dioiodine could be considered. If radioiodine is being con-
sidered, prior external beam radiotherapy and concomitant
glucocorticoid therapy are strongly recommended to mini-
mize the effects of a potential TSH-induced increase in tu-
mor size and the subsequent inflammatory effects of the ra-
dioiodine (261)—Recommendation C
Management of complications of radioiodine therapy.
While radioiodine appears to be a reasonably safe therapy,
it is associated with a cumulative dose-related low risk of
early and late onset complications such as salivary gland
damage, nasolacrimal duct obstruction (268), and secondary
malignancies (267). Therefore, it is important to ensure that
the benefits of repeated radioiodine therapy outweigh the
potential risks. There is probably no dose of radioactive io-
dine that is completely safe nor is there any maximum cu-
mulative dose that could not be used in selected situations.
However, with higher individual and cumulative doses there
are increased risks of side effects as discussed previously.
R71. For acute transient loss of taste or change in taste and
sialadenitis, some have recommended measures to prevent
damage to the salivary glands including amifostine, hydra-
tion, sour candies and cholinergic agents (268), but evidence
is insufficient to recommend for or against these modalities.
One recent study suggested sour candy may actually in-
crease salivary gland damage when given within 1 hour of
radioiodine therapy, compared to its use until 24 hours post-
therapy (269). For chronic salivary gland complications, such
as dry mouth and dental caries, cholinergic agents may in-
crease salivary flow (268)—Recommendation I
R72. Patients with xerostomia are at increased risk of dental
caries and should discuss preventative strategies with their
dentists—Recommendation C
R73. Surgical correction should be considered for naso-
lacrimal outflow obstruction, which often presents as exces-
sive tearing (epiphora) but also predisposes to infection—
Recommendation B
Second malignancies and leukemia from radioiodine ther-
apy. Long-term follow-up studies demonstrate a very low
risk of secondary malignancies (bone and soft tissue malig-
nancies, colorectal cancer, salivary tumors, and leukemia) in
long-term survivors (267). The risk of secondary malignan-
cies is dose-related (267). There appears to be an increased
risk of breast cancer in women with thyroid cancer (270). It
is unclear whether this is the result of screening bias, ra-
dioiodine therapy, or other factors.
R74. Because there is no evidence demonstrating a benefit of
more intensive screening, all patients with thyroid cancer
should be encouraged to seek age-appropriate screenings for
cancer according to routine health maintenance recommen-
dations—Recommendation C
Other risks to the bone marrow from radioiodine therapy.
Published data indicate that when administered activities are
selected to remain below 200 cGy to the bone marrow, min-
imal transient effects are noted in white blood cell (WBC)
and platelet counts (254). However, persistent mild decre-
ments in white blood count and/or platelets are not un-
common in patients who have received multiple radioiodine
therapies. Furthermore, radiation to the bone marrow is im-
pacted by several factors, including renal function.
R75. Patients receiving therapeutic doses of radioiodine
should have baseline complete blood cell (CBC), platelet
count and assessment of renal function—Recommendation C
Effects of radioiodine on gonadal function and in breast-
feeding women. Gonadal tissue is exposed to radiation from
radioiodine in the blood, urine and feces. Temporary amen-
orrhea/oligomenorrhea lasting 4–10 months occurs in
20%–27% of menstruating women after 131I therapy for thy-
roid cancer. Although the numbers of patients studied are
small, long-term rates of infertility, miscarriage, and fetal
malformation do not appear to be elevated in women after
radioiodine therapy (271,272). One large retrospective study
suggested that pregnancy should be postponed for 1 year af-
ter therapy because of an increase in miscarriage rate (273).
Ovarian damage from radioiodine therapy may result in
menopause occurring approximately 1 year earlier than the
general population, but this result was not associated with
cumulative dose administered or the age at which the ther-
apy was given (274). In men, radioiodine therapy may be as-
sociated with a temporary reduction in sperm counts and 
elevated serum follicle-stimulating hormone (FSH) levels
(275,276). Higher cumulative doses (500–800 mCi) in men are
associated with an increased risk of persistent elevation of
serum FSH levels, but fertility and risks of miscarriage or
congenital abnormalities in subsequent pregnancies are not
changed with moderate radioiodine doses (approximately
200 mCi) (277,278). Permanent male infertility is unlikely
with a single ablative dose of radioiodine, but theoretically
there could be cumulative damage with multiple treatments.
It has been suggested that sperm banking be considered in
men who may receive cumulative radioiodine doses 400 mCi
or more (278). Gonadal radiation exposure is reduced with
good hydration, frequent micturition to empty the bladder
and avoidance of constipation (279).
R76. Women receiving radioactive iodine therapy should
avoid pregnancy for 6–12 months—Recommendation B 
R77. Radioactive iodine should not be given to breast-feed-
ing women. Depending on the clinical situation, radioiodine
therapy could be deferred until a time when lactating women
have stopped breast-feeding for at least 6–8 weeks.
Dopaminergic agents might be useful in decreasing breast
exposure, although caution should be exercised given the
risk of serious side-effects associated with their routine use
to suppress postpartum lactation—Recommendation B
How should thyroglobulin-positive patients be managed?
If the unstimulated thyroglobulin is or becomes detectable
or stimulated thyroglobulin levels rise to greater than 2 ng/mL,
imaging of the neck and chest should be performed to search
for metastatic disease, typically with neck ultrasound and with
thin-cut (5–7 mm) helical chest CT. Iodinated contrast should
be avoided if radioiodine therapy is planned within the sub-
sequent few months, although intravenous contrast may aid
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in identification of mediastinal disease. If imaging is negative
for disease that is potentially curable by surgery, then empiric
therapy with radioiodine (100–200 mCi) should be considered
to aid localization or for therapy of surgically incurable dis-
ease (Fig. 4). This approach may identify the location of per-
sistent disease in approximately 50% of patients (203,280) with
a wide range of reported success. Some investigators have re-
ported a decrease in serum thyroglobulin after empiric ra-
dioiodine therapy in patients with negative RxWBS (281,282),
but there is no evidence for improved survival with empiric
therapy in this setting (258,283). On the other hand, serum thy-
roglobulin levels may decline without specific therapy (282).
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FIG. 4. Considerations for empiric treatment with radioiodine. nThyroglobulin (Tg) that rises with thyrotropin (TSH) stim-
ulation and falls with TSH suppression is unlikely to result from heterophile antibodies. oNational Cancer Institute Com-
mon Terminology Criteria for Adverse Events, Version 3.0, (www.ctep.cancer.gov). pLithium may be beneficial at this point
but there are few clinical studies. qDxWBS is diagnostic whole-body scintigraphy. rFDG-PET scanning sensitivity and speci-
ficity may be enhanced with stimulation (rhTSH or THW) and by fusion with CT imaging (PET/CT). sDosimetry could be
considered to allow administration of maximum radioiodine activity if the tumor is life-threatening. (Reprinted with per-
mission from J Nucl Med 46:1079–1088, 2005.)
A cutoff value of thyroglobulin above which a patient
should be treated with an empiric dose of radioiodine is dif-
ficult to determine, in part because of the wide variation in
available thyroglobulin assays (including those used in re-
ports suggesting benefit of such therapy) and the differences
in thyroglobulin levels based on method and degree of TSH
stimulation or suppression. Recent studies have reported pri-
marily on patients with thyroglobulin levels after thyroxine
withdrawal of 10 ng/mL or higher, and it has been suggested
that a corresponding level after rTSH stimulation would be
5 ng/mL (204,256,280,282,283). A thyroglobulin level that is
rising may warrant greater concern for the need for empiric
therapy, although data regarding the appropriate rate of
change are minimal (202).
R78. Empiric radioactive iodine therapy (100–200 mCi) might
be considered in patients with elevated or rising serum thy-
roglobulin levels in whom imaging has failed to reveal a po-
tential tumor source—Recommendation C
R79. If persistent nonresectable disease is localized after an
empiric dose of radioiodine, and there is objective evidence
of significant tumor reduction, then radioiodine therapy
should be repeated until the tumor has been eradicated or
the tumor no longer responds to treatment. The risk of re-
peated therapeutic does of radioiodine must be balanced
against uncertain long-term benefits—Recommendation C
Patients with a negative posttreatment whole-body scan
(RxWBS)
R80. If an empiric dose (100–200 mCi) of radioiodine fails to
localize the persistent disease, 18FDG-PET scanning should
be considered, especially in patients with unstimulated
serum thyroglobulin levels more than 10–20 ng/ml, in order
to localize metastatic lesions that may require treatment or
continued close observation (284,285)—Recommendation B
Stimulation with endogenous TSH after thyroxine with-
drawal or rhTSH (286) and CT fusion (287) may enhance the
sensitivity and specificity of FDG-PET scanning.
R81. Thyroglobulin positive, RxWBS-negative patients with
disease that is incurable with surgery and is structurally evi-
dent or visualized on FDG-PET scan can be managed with
thyroid hormone suppression therapy, external beam radio-
therapy, chemotherapy, radiofrequency ablation, chemoem-
bolization, or monitoring without additional therapy if stable.
Clinical trials should also be considered—Recommendation C
R82. Thyroglobulin-positive, RxWBS-negative patients with
no structural evidence of disease can be followed with ser-
ial structural imaging studies and serial thyroglobulin mea-
surements, with both performed more frequently if the thy-
roglobulin level is rising. When and how often to repeat
FDG-PET imaging in this setting is less certain—Recom-
mendation C
What is the role of external beam radiotherapy in
treatment of metastatic disease?
R83. External beam radiation should be used in the man-
agement of unresectable gross residual cervical disease,
painful bone metastases, metastatic lesions in critical loca-
tions likely to result in fracture, neurological, or compressive
symptoms that are not amenable to surgery (e.g., vertebral
metastases, CNS metastases, selected mediastinal or sub-
carinal lymph nodes, pelvic metastases) (174,226)—Recom-
mendation B
What is the role of chemotherapy in the treatment of
metastatic disease?
Studies of chemotherapy for advanced, radioiodine-resis-
tant differentiated thyroid carcinoma are limited. Doxoru-
bicin monotherapy may be effective in up to 40% of patients
(most partial response or stable disease) when dosed appro-
priately (60–75 mg/m2 every 3 weeks) (288–291) but durable
responses are uncommon. Most studies of combination che-
motherapy show no increased response over single agent
doxorubicin and increased toxicity (292). Some specialists rec-
ommend consideration of single agent doxorubicin or pacli-
taxel, or a combination of these agents based on limited data
in anaplastic thyroid carcinoma (293). One recent study eval-
uated the effect of combination chemotherapy (carboplat-
inum and epirubicin) under TSH stimulation (endogenous or
rhTSH) (294), demonstrating an overall rate of complete and
partial response of 37%. These data need to be confirmed
prior to consideration for general use.
R84. Chemotherapy has modest benefit in patients with ad-
vanced, radioiodine-resistant thyroid cancer. Patients with
progressive disease should first be considered for clinical tri-
als. If clinical trials are unavailable or the patient prefers stan-
dard cytotoxic chemotherapy, doxorubicin used as a single
agent or in combination with other agents may be consid-
ered—Recommendation C
Should patients skip chemotherapy and instead opt for
clinical trials?
If the patient qualifies for a clinical trial, they should con-
sider bypassing traditional chemotherapy and moving di-
rectly to clinical trials. However, patients often cannot par-
ticipate in clinical trials because of the time and expense
required, or failure to meet strict eligibility criteria. Most
available trials can be found listed at www.clinicaltrials.
gov; www.nci.nih.gov; www.centerwatch.com; or www.thy-
roid.org
R85. Patients with advanced, progressive, unresectable ra-
dioiodine non-responsive thyroid cancer who are being con-
sidered for chemotherapy should be considered for entry
into clinical trials—Recommendation C
What Are the Directions for Future Research?
Novel therapies and clinical trials
While surgery and the judicious use of radioactive iodine,
as described in these guidelines, is sufficient treatment for
the majority of patients with differentiated thyroid cancer, a
minority of these patients experiences progressive, life-
threatening growth and metastatic spread of the disease. For
these individuals, experimental treatments may be consid-
ered. Several clinical trials are already in progress; others are
at various stages of development and the number of avail-
able clinical trials is likely to grow rapidly. The recent ex-
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plosion of knowledge regarding the molecular and cellular
pathogenesis of cancer has led to the development of a range
of targeted therapies, now beginning clinical evaluation.
These therapies can be grouped into a number of categories:
Oncogene inhibitors. Tyrosine kinase inhibitors target the
activated RET/PTC oncogene, responsible for a proportion
of PTC. Inhibitors of RAS, RAF, and MEK kinase target var-
ious members of the same signaling pathway. Several of
these agents are in development, with at least one clinical
trial underway. Specific oncogene targeting for follicular thy-
roid cancer and Hürthle thyroid cancer awaits better under-
standing of the pathways involved in initiation of these tu-
mor types.
Modulators of growth or apoptosis. Key components of
growth and apoptotic pathways are targeted by PPAR ac-
tivators, including COX2 inhibitors; retinoids, which activate
PPAR/RXR heterodimers; Bortezomib (Velcade®, Mille-
nium Pharmaceuticals, Cambridge, MA), which inactivates
the cancer proteasome; and derivatives of geldanomycin,
which target the hsp-90 protein. Clinical trials in thyroid can-
cer of each of these agents are available.
Angiogenesis inhibitors. Targeting of vascular endothelial
growth factor (VEGF) and other members of the signaling
cascade responsible for neoangiogenesis may limit the
growth of cancers by restricting their blood supply. Trials of
several of these agents are currently underway in both
anaplastic and differentiated thyroid cancer.
Immunomodulators. Stimulation of the immune response
to cancer may be achieved by augmenting the activity of anti-
gen-presenting dendritic cells. This approach has shown pos-
sible benefits in phase 1 clinical trials, but has not yet been
studied in thyroid cancer. The apparent immunogenicity of
thyroid cells makes this an attractive approach for future
clinical trials.
Gene therapy. Preclinical studies have demonstrated some
efficacy in thyroid cancer cell lines. Approaches include in-
troducing toxic genes under the control of thyroid-specific
promoters, or restoration of the p53 tumor-suppressor gene
in anaplastic thyroid cancer cell lines. Problems with gene
delivery limit the clinical utility of these approaches, which
have not yet reached clinical trials in thyroid cancer.
Each of these targeted approaches holds promise for our
future ability treat patients with life-threatening disease un-
responsive to traditional therapy. In the meantime, for ap-
propriate patients, entry into one of the available clinical tri-
als may be an attractive option.
Better understanding of the long term-risks of radioiodine
With the more widespread use of radioactive iodine in the
management of thyroid cancer, it is imperative that we have
a better understanding of the long-term risks associated with
its use. Research that focuses on how to minimize the im-
pact of radioiodine on the salivary glands in order to pre-
vent siladenitis and xerostomia would provide a significant
benefit to patients. A better understanding of the long-term
effects of radioiodine on reproductive issues in men and
women is also an important topic. Finally, while the risk of
second malignancies appears small following the usual doses
of radioiodine used for remnant ablation, we need better un-
derstanding of the long-term risks for salivary gland tumors,
gastrointestinal tumors, bladder tumors, and colon cancers
when repeated doses of radioiodine are needed in young pa-
tients with potentially curable thyroid cancer.
Clinical significance of persistent low-level thyroglobulin
After initial surgery and radioiodine therapy some pa-
tients will have persistently detectable stimulated serum thy-
roglobulin when evaluated 9–12 months later. Most of these
patients have stimulated thyroglobulin levels in the range of
1–10 ng/mL, levels typically associated with a small volume
of tissue. Some of these patients demonstrate a subsequent
spontaneous fall in thyroglobulin over time, others remain
stable, while still others demonstrate rising thyroglobulin
levels. The optimal management of these patients is un-
known. How often should they undergo neck ultrasound or
stimulated serum thyroglobulin testing? Which (if any) of
these patients undergo chest CT, PET, or empiric radioiodine
therapy? Can we improve our abilities to predict and mon-
itor which patients are likely to be harmed by their disease
as opposed to those who will live unaffected by theirs? Does
metastatic disease in small local lymph nodes have the po-
tential to metastasize to distant sites during observation
while on TSH-suppression therapy? The current impetus to
test and treat all of these patients is based on the argument
that early diagnosis may lead to early treatment of residual
disease when treatment is more likely to be effective, as op-
posed to less effective treatment when the tumor is more
bulky, more extensive, or spread to inoperable locations.
However, there is no current proof that aggressive treatment
of minimal residual disease improves patient outcome. This
is brought into focus by the fact that only about 5% of PTC
patients die of their disease, yet more than one third of PTC
patients are likely to have persistent disease based on per-
sistent measurable thyroglobulin to stimulation testing.
The problem of thyroglobulin antibodies
Antithyroglobulin antibodies are a common clinical prob-
lem in patients with differentiated thyroid carcinoma (20%)
(198). The presence of these antibodies usually interferes
with serum thyroglobulin measurement and recovery as-
says do not appear to accurately predict this interference
(198,295). Decreasing antibody levels are correlated with
“disease-free” status while increasing levels suggest persis-
tent disease (199,296). Measurement of thyroglobulin mRNA
in the blood may be a sensitive marker for persistent thyroid
cells even in the presence of anti-thyroglobulin antibodies
(297–299), but RNA extraction is not well standardized and
some studies question the specificity of this marker (300,301).
Future studies optimizing thyroglobulin mRNA measure-
ments in blood from DTC patients with antithyroglobulin
antibodies, further development of thyroglobulin assays that
have limited interference by antithyroglobulin antibodies or
methods to clear antithyroglobulin antibodies prior to thy-
roglobulin measurement are needed to better monitor this
challenging subgroup of patients with DTC.
Small cervical lymph node metastases
The rates of cervical lymph node metastases generally
range from about 20%–50% in most large series of differen-
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tiated thyroid carcinoma, with higher rates in children or
when mircometastases are considered. The location and num-
ber of lymph node metastases is often difficult to identify at
before or at the time of surgery, especially micrometastases.
Although postoperative 131I given to ablate the thyroid rem-
nant undoubtedly destroys some micrometastases, the most
common site of recurrence is in cervical lymph nodes, which
comprises the majority of all recurrences. Future research
must be directed to developing techniques to identify small
cervical metastases, which in a substantial number of cases
progress to overt, clinically significant metastases.
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